Evidence map›Paper›PMID 36559331›Full record

ArticlePharmaceutics2022

Chemical Attachment of 5-Nitrosalicylaldimine Motif to Silatrane Resulting in an Organic-Inorganic Structure with High Medicinal Significance.

Mirela-Fernanda Zaltariov, Mihaela Turtoi, Dragos Peptanariu, Ana-Maria Macsim, Lilia Clima, Corneliu Cojocaru, Nicoleta Vornicu, Bianca-Iulia Ciubotaru, Alexandra Bargan, Manuela Calin and 1 more

Open access · goldAbstract read
In one paragraph

Article in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Mirela-Fernanda ZaltariovInorganic Polymers Department, "Petru Poni" Institute of Macromolecular Chemistry, Aleea Gr. Ghica Voda 41 A, 700487 Iasi, Romania.ORCID 0000-0001-6692-0481
Mihaela TurtoiMedical and Pharmaceutical Bionanotechnologies Laboratory, Institute of Cellular Biology and Pathology "Nicolae Simionescu" of the Romanian Academy, B.P. Hasdeu 8, 050568 Bucharest, Romania.ORCID 0000-0001-6418-3406
Dragos PeptanariuCentre of Advanced Research in Bionanoconjugates and Biopolymers, "Petru Poni" Institute of Macromolecular Chemistry, Aleea Gr. Ghica Voda 41 A, 700487 Iasi, Romania.ORCID 0000-0001-8108-3765
Ana-Maria MacsimNMR Laboratory, "Petru Poni" Institute of Macromolecular Chemistry, Aleea Gr. Ghica Voda 41 A, 700487 Iasi, Romania.ORCID 0000-0002-5107-6369
Lilia ClimaCentre of Advanced Research in Bionanoconjugates and Biopolymers, "Petru Poni" Institute of Macromolecular Chemistry, Aleea Gr. Ghica Voda 41 A, 700487 Iasi, Romania.ORCID 0000-0003-0103-2277
Corneliu CojocaruInorganic Polymers Department, "Petru Poni" Institute of Macromolecular Chemistry, Aleea Gr. Ghica Voda 41 A, 700487 Iasi, Romania.ORCID 0000-0002-3651-6178
Nicoleta VornicuMetropolitan Center of Research T.A.B.O.R, The Metropolitanate of Moldavia and Bukovina, 700066 Iasi, Romania.ORCID 0000-0002-4025-2582
Bianca-Iulia CiubotaruInorganic Polymers Department, "Petru Poni" Institute of Macromolecular Chemistry, Aleea Gr. Ghica Voda 41 A, 700487 Iasi, Romania.
Alexandra BarganInorganic Polymers Department, "Petru Poni" Institute of Macromolecular Chemistry, Aleea Gr. Ghica Voda 41 A, 700487 Iasi, Romania.ORCID 0000-0002-9433-9595
Manuela CalinMedical and Pharmaceutical Bionanotechnologies Laboratory, Institute of Cellular Biology and Pathology "Nicolae Simionescu" of the Romanian Academy, B.P. Hasdeu 8, 050568 Bucharest, Romania.ORCID 0000-0002-5245-160X
Maria CazacuInorganic Polymers Department, "Petru Poni" Institute of Macromolecular Chemistry, Aleea Gr. Ghica Voda 41 A, 700487 Iasi, Romania.ORCID 0000-0003-4952-5548
Romanian Academy · RO

Funding

Unitatea Executiva Pentru Finantarea Invatamantului Superior a Cercetarii Dezvoltarii si Inovarii PN-III-P4-ID-PCCF-2016-0050, Contract 4/2018, 5DnanoP
6 · The paper itself

Abstract

Two chemical motifs of interest for medicinal chemistry, silatrane as 1-(3-aminopropyl) silatrane (SIL M), and nitro group attached in position 5 to salicylaldehyde, are coupled in a new structure, 1-(3-{[(2-hydroxy-5-nitrophenyl)methylidene]amino}propyl)silatrane (SIL-BS), through an azomethine moiety, also known as a versatile pharmacophore. The high purity isolated compound was structurally characterized by an elemental, spectral, and single crystal X-ray diffraction analysis. Given the structural premises for being a biologically active compound, different specific techniques and protocols have been used to evaluate their in vitro hydrolytic stability in simulated physiological conditions, the cytotoxicity on two cancer cell lines (HepG2 and MCF7), and protein binding ability-with a major role in drug ADME (Absorption, Distribution, Metabolism and Excretion), in parallel with those of the SIL M. While the latter had a good biocompatibility, the nitro-silatrane derivative, SIL-BS, exhibited a higher cytotoxic activity on HepG2 and MCF7 cell lines, performance assigned, among others, to the known capacity of the nitro group to promote a specific cytotoxicity by a "activation by reduction" mechanism. Both compounds exhibited increased bio- and muco-adhesiveness, which can favor an optimized therapeutic effect by increased drug permeation and residence time in tumor location. Additional benefits of these compounds have been demonstrated by their antimicrobial activity on several fungi and bacteria species. Molecular docking computations on Human Serum Albumin (HSA) and M

Indexed as

1-(3-aminopropyl)silatrane2-hydroxy-5-nitrobenzaldehydeazomethinecytotoxicityprotein binding

Identifiers

PMID36559331
PMCPMC9781643
OpenAlexW4312195748

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.